サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1782998

ペプチド抗生物質の世界市場

Peptide Antibiotics

出版日
ページ情報
英文 381 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.84円
ペプチド抗生物質の世界市場
出版日: 2025年08月04日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 381 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ペプチド抗生物質の世界市場は2030年までに61億米ドルに達する見込み

2024年に48億米ドルと推定されるペプチド抗生物質の世界市場は、2024年から2030年にかけてCAGR 3.9%で成長し、2030年には61億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである非リボソーム合成ペプチド抗生物質は、CAGR 4.6％を記録し、分析期間終了までに43億米ドルに達すると予測されます。リボソーム合成ペプチド抗生物質分野の成長率は、分析期間中CAGR 2.5％と推定されます。

米国市場は13億米ドルと推定、中国はCAGR 7.4％で成長予測

米国のペプチド抗生物質市場は、2024年に13億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに12億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.6%と3.1%と予測されています。欧州では、ドイツがCAGR 2.3%で成長すると予測されています。

世界のペプチド抗生物質市場- 主要動向と促進要因のまとめ

ペプチド抗生物質とは何か？

ペプチド抗生物質は、ペプチドとして知られるアミノ酸の短い鎖からなる抗生物質の一種であり、抗菌特性を有しています。これらの天然または合成ペプチドは、細菌、真菌、その他の病原体に対して幅広いスペクトラム活性を示し、従来の低分子抗生物質の重要な代替となります。ペプチド抗生物質は通常、微生物の細胞膜を破壊することによって機能し、それによって細胞溶解と死滅を引き起こします。ペプチド抗生物質は細菌膜に結合して孔を開け、細胞内容物を漏出させ、最終的に細菌を死滅させる。さらに、ペプチド抗生物質の中には、特定の細胞内経路を標的とし、タンパク質合成やその他の必須細胞機能を阻害するものもあります。

主に特定の細菌の酵素や経路を標的にする従来の抗生物質とは異なり、ペプチド抗生物質は多剤耐性菌を含むより広範囲の病原体を攻撃できる、より汎用性の高い抗生物質であることが多いです。このため、世界の健康危機となっている抗生物質耐性の懸念の高まりに対処する上で、ペプチド抗生物質は特に有用です。ペプチド抗生物質は、ディフェンシン、マゲイニン、バンコマイシンなどの天然物や、有効性と安定性を向上させるために研究室で設計された合成ペプチドなど、様々な形で見出されています。これらの抗生物質は、従来の抗生物質が効きにくい感染症、特に耐性菌による感染症の治療に有望視されています。

なぜペプチド抗生物質市場は拡大しているのか？

ペプチド抗生物質市場は、抗生物質耐性感染症の増加、ヘルスケア関連感染（HAI）の発生率の増加、多剤耐性病原体の治療における現在の抗生物質の限界により拡大しています。抗生物質耐性は、公衆衛生上の最も重大な課題の1つとして浮上しています。細菌やその他の病原体が、既存の抗生物質の多くに耐えられるように進化してきたからです。この耐性により、より効果的な新しい治療法の開発が急務となっており、耐性感染症に対する有望な解決策として、ペプチド抗生物質が大きな注目を集めています。

ヘルスケア関連感染（HAI）の増加も、ペプチド抗生物質市場を牽引する要因の一つです。病院内で発生し、手術を受ける患者に影響を及ぼすこれらの感染症は、薬剤耐性菌によって引き起こされることが多く、患者の健康に深刻なリスクをもたらします。このような状況において、ペプチド抗生物質は、メチシリン耐性黄色ブドウ球菌（MRSA）やクロストリジウム・ディフィシル（C. difficile）など、病院で一般的に見られる耐性菌に対する有効性が実証されており、潜在的な治療オプションとして検討されています。ペプチド抗生物質は、従来の抗生物質に耐性を持つ細菌を含む幅広い細菌を標的とすることができるため、治療が困難な感染症に対処するための貴重なツールとなります。

さらに、ペプチドベースの治療薬への関心の高まり、ペプチド合成やドラッグデリバリー技術の進歩が、新しいペプチド抗生物質の開発を促進しています。これらの進歩により、より強力で安定したペプチド抗生物質の生産が可能になり、治療の可能性が広がり、標準的な抗生物質に耐性を持つようになった感染症の治療能力が向上しています。製薬業界が新しいペプチド抗生物質を発見するために研究開発への投資を続けているため、これらの治療市場は成長すると予想されます。

ペプチド抗生物質の将来を形作る主な動向は？

ペプチド抗生物質市場の将来は、抗生物質耐性への継続的な注目、ペプチドデザインと製剤化の進歩、併用療法の一部としてのペプチドの使用の増加など、いくつかの主要動向によって形成されます。主な動向の一つは、抗菌薬耐性（AMR）の増加に対抗するための新規ペプチド抗生物質の発見と開発に重点が置かれていることです。世界各国の政府やヘルスケア機関は、多剤耐性病原体の脅威への対応として、ペプチドベースの薬剤を含む新規抗生物質の開発を奨励する取り組みに投資しています。この動向は、耐性感染症に対抗する方法として、ペプチド抗生物質の可能性に関する研究の増加を促しています。

ペプチド設計と製剤化の進歩もまた、市場の将来を大きく左右しています。研究者は、半減期が短く人体内で分解されやすいペプチド抗生物質の安定性、バイオアベイラビリティ、安全性プロファイルの改善に注力しています。ペプチド類似体、ペプチド模倣体、コンジュゲートの開発などの新しい戦略により、科学者はこれらの制限を克服し、ペプチド抗生物質の臨床的有用性を高めることができます。さらに、ナノ粒子やリポソームなどのドラッグデリバリー技術の進歩により、ペプチド抗生物質の効率とターゲティングが改善され、感染症治療により効果的になってきています。

もう一つの新たな動向は、ペプチド抗生物質を他の抗菌剤や治療法と併用することへの関心の高まりです。併用療法とは、ペプチド抗生物質を従来の抗生物質や他のクラスの薬剤と組み合わせて使用することで、治療成績を向上させ、耐性菌対策にも役立ちます。異なる作用機序を利用することで、併用療法は治療効果を高め、耐性菌の発生を抑え、各薬剤の用量を少なくして副作用を最小限に抑えることができます。この動向は、特に重症・多剤耐性感染症の治療において、ペプチド抗生物質の臨床的成功率を向上させる方法を研究者が探求し続けていることから、牽引力を増しています。

ペプチド抗生物質市場の成長促進要因は？

ペプチド抗生物質市場の成長は、抗生物質耐性感染症の増加、慢性疾患の増加、ペプチド合成技術の進歩など、いくつかの要因によってもたらされます。抗生物質耐性の増加は、ペプチド抗生物質の需要に寄与する最も重要な要因の一つです。従来の抗生物質が耐性病原体に対する有効性を失う中、ペプチド抗生物質はこの増大する問題に対する潜在的な解決策を提供します。ペプチド抗生物質は、従来の治療に耐性を持つ細菌種を含む幅広い細菌種をターゲットにできることが、市場成長の主な促進要因となっています。

抗生物質耐性に加え、慢性疾患や院内感染の増加も新たな抗生物質治療への需要を押し上げています。糖尿病やがんなどの慢性疾患では、長期入院や外科手術が必要になることが多く、耐性菌による感染症のリスクが高まる。ペプチド抗生物質は、幅広いスペクトラム活性と治療困難な病原体を標的とする能力を有しており、このような環境における潜在的な治療選択肢として検討されています。世界の人口が高齢化し、慢性疾患の負担が増加し続ける中、これらの脆弱な人々の感染症を管理するための効果的な治療に対するニーズが、ペプチド抗生物質の市場を牽引すると予想されます。

ペプチド合成技術の進歩も市場成長に寄与しています。ペプチドの効率的でスケーラブルな生産を可能にする固相ペプチド合成（SPPS）の最近の技術革新により、ペプチド抗生物質は製薬会社にとってより利用しやすくなり、費用対効果も向上しました。これにより、有効性と安全性が改善された新世代のペプチド抗生物質が開発されました。さらに、製薬会社や学術機関による研究開発への投資の増加は、新しいペプチド抗生物質の発見を加速させ、治療の可能性を広げ、市場を前進させるのに役立っています。

最後に、生物製剤が受け入れられ、個別化医療への関心が高まっていることが、ペプチド抗生物質に新たな機会をもたらしています。ヘルスケア産業が、よりターゲットを絞った個別化治療へとシフトする中、ペプチド抗生物質は、より特異的で副作用の少ない幅広い感染症の治療に有望なアプローチを提供します。ペプチドベースの治療法の研究が拡大するにつれ、ペプチド抗生物質が個別化された治療レジメンに使用される可能性は拡大し続け、市場の需要はさらに高まるでしょう。

セグメント

製品タイプ（非リボソーム合成ペプチド抗生物質、リボソーム合成ペプチド抗生物質）、疾患タイプ（皮膚感染症、HABP/VABP、血流感染症、その他の疾患タイプ）、流通チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例

  • AbbVie Inc.
  • Acurx Pharmaceuticals
  • ANI Pharmaceuticals, Inc.
  • Antabio
  • BiomX
  • Clarametyx Biosciences
  • Cubist Pharmaceuticals（acquired by Merck & Co.）
  • Cumberland Pharmaceuticals Inc.
  • Eli Lilly and Company
  • GSK plc.
  • Melinta Therapeutics
  • Merck & Co., Inc.
  • MinervaX
  • Pfizer Inc.
  • Sandoz AG
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • The Menarini Group
  • Venatorx Pharmaceuticals
  • Xellia Pharmaceuticals

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMをクエリする代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP32517

Global Peptide Antibiotics Market to Reach US$6.1 Billion by 2030

The global market for Peptide Antibiotics estimated at US$4.8 Billion in the year 2024, is expected to reach US$6.1 Billion by 2030, growing at a CAGR of 3.9% over the analysis period 2024-2030. Non-ribosomal Synthesized Peptide Antibiotics, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$4.3 Billion by the end of the analysis period. Growth in the Ribosomal Synthesized Peptide Antibiotics segment is estimated at 2.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 7.4% CAGR

The Peptide Antibiotics market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 7.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR.

Global Peptide Antibiotics Market - Key Trends & Drivers Summarized

What Are Peptide Antibiotics and How Do They Work?

Peptide antibiotics are a class of antibiotics composed of short chains of amino acids, known as peptides, that have antimicrobial properties. These naturally occurring or synthetic peptides exhibit broad-spectrum activity against bacteria, fungi, and other pathogens, making them an important alternative to traditional small-molecule antibiotics. Peptide antibiotics typically function by disrupting the microbial cell membrane, thereby causing cell lysis and death. They can bind to bacterial membranes and create pores, leading to leakage of cellular contents, which ultimately kills the bacteria. Additionally, some peptide antibiotics target specific intracellular pathways, inhibiting protein synthesis or other essential cellular functions.

Unlike traditional antibiotics that primarily target specific bacterial enzymes or pathways, peptide antibiotics are often more versatile, capable of attacking a wider range of pathogens, including multidrug-resistant bacteria. This makes them particularly valuable in addressing the growing concern of antibiotic resistance, which has become a global health crisis. Peptide antibiotics are found in a variety of forms, including natural products such as defensins, magainins, and vancomycin, as well as synthetic peptides designed in laboratories to improve efficacy and stability. These antibiotics have shown promise in treating infections that do not respond well to conventional antibiotics, particularly those caused by resistant strains of bacteria.

Why Is the Peptide Antibiotics Market Expanding?

The peptide antibiotics market is expanding due to the rising prevalence of antibiotic-resistant infections, the increasing incidence of healthcare-associated infections (HAIs), and the limitations of current antibiotics in treating multidrug-resistant pathogens. Antibiotic resistance has emerged as one of the most critical public health challenges, as bacteria and other pathogens have evolved to withstand many of the existing antibiotics. This resistance has led to an urgent need for new and more effective treatments, and peptide antibiotics have gained significant attention as a promising solution to combat resistant infections.

The growing incidence of healthcare-associated infections (HAIs) is another driving factor for the peptide antibiotics market. These infections, which occur in hospital settings and affect patients undergoing surgeries, are often caused by drug-resistant bacteria and pose serious risks to patient health. In this context, peptide antibiotics are being explored as potential treatment options, as they have demonstrated effectiveness against resistant bacterial strains commonly found in hospitals, such as methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile (C. difficile). The ability of peptide antibiotics to target a broad range of bacteria, including those resistant to conventional antibiotics, makes them a valuable tool in addressing these difficult-to-treat infections.

Moreover, the growing interest in peptide-based therapeutics, as well as advancements in peptide synthesis and drug delivery technologies, has facilitated the development of new peptide antibiotics. These advances allow for the production of more potent and stable peptide antibiotics, expanding their therapeutic potential and enhancing their ability to treat infections that have become resistant to standard antibiotics. As the pharmaceutical industry continues to invest in research and development to discover novel peptide antibiotics, the market for these treatments is expected to grow.

What Key Trends Are Shaping the Future of Peptide Antibiotics?

The future of the peptide antibiotics market is shaped by several key trends, including the ongoing focus on antibiotic resistance, advancements in peptide design and formulation, and the increasing use of peptides as part of combination therapies. One of the major trends is the growing emphasis on discovering and developing novel peptide antibiotics to combat the rise of antimicrobial resistance (AMR). Governments and healthcare organizations worldwide are investing in initiatives to encourage the development of new antibiotics, including peptide-based drugs, as a response to the threat of multidrug-resistant pathogens. This trend is driving increased research into the potential of peptide antibiotics as a way to combat resistant infections.

Advancements in peptide design and formulation are also significantly shaping the market's future. Researchers are focusing on improving the stability, bioavailability, and safety profile of peptide antibiotics, which can often be limited by their short half-lives and susceptibility to degradation in the human body. New strategies, such as the development of peptide analogs, peptide mimetics, and conjugates, are enabling scientists to overcome these limitations and enhance the clinical utility of peptide antibiotics. Additionally, advancements in drug delivery technologies, such as nanoparticles and liposomes, are improving the efficiency and targeting of peptide antibiotics, making them more effective in treating infections.

Another emerging trend is the increasing interest in using peptide antibiotics in combination with other antimicrobial agents or therapies. Combination therapies, where peptide antibiotics are paired with traditional antibiotics or other classes of drugs, can improve treatment outcomes and help address resistance. By using different mechanisms of action, combination therapies can enhance the overall effectiveness of treatment, reduce the development of resistance, and allow for the use of lower doses of each drug, minimizing side effects. This trend is gaining traction as researchers continue to explore ways to improve the clinical success rates of peptide antibiotics, especially in the treatment of severe and multidrug-resistant infections.

What Are the Key Drivers of Growth in the Peptide Antibiotics Market?

The growth of the peptide antibiotics market is driven by several factors, including the increasing prevalence of antibiotic-resistant infections, the growing number of chronic diseases, and the advancements in peptide synthesis technologies. The rise of antibiotic resistance is one of the most significant factors contributing to the demand for peptide antibiotics. As traditional antibiotics lose their efficacy against resistant pathogens, peptide antibiotics offer a potential solution to this growing problem. The ability of peptide antibiotics to target a wide range of bacterial species, including those resistant to conventional treatments, is a major driver of their market growth.

In addition to antibiotic resistance, the increasing prevalence of chronic diseases and hospital-acquired infections is driving the demand for new antibiotic treatments. Chronic conditions such as diabetes and cancer often require long-term hospital stays and surgical interventions, which increase the risk of infections caused by resistant bacteria. Peptide antibiotics, with their broad-spectrum activity and ability to target difficult-to-treat pathogens, are being explored as potential treatment options in these settings. As the global population ages and the burden of chronic diseases continues to grow, the need for effective treatments to manage infections in these vulnerable populations is expected to drive the market for peptide antibiotics.

Advancements in peptide synthesis technologies are also contributing to market growth. Recent innovations in solid-phase peptide synthesis (SPPS), which enable the efficient and scalable production of peptides, have made peptide antibiotics more accessible and cost-effective for pharmaceutical companies. This has led to the development of a new generation of peptide antibiotics with improved efficacy and safety profiles. Furthermore, the increasing investment in research and development by pharmaceutical companies and academic institutions is helping to accelerate the discovery of new peptide antibiotics, expanding their therapeutic potential and driving the market forward.

Finally, the growing acceptance of biologics and the increasing interest in personalized medicine are providing new opportunities for peptide antibiotics. As the healthcare industry shifts toward more targeted and individualized treatments, peptide antibiotics offer a promising approach for treating a wide range of infections with greater specificity and fewer side effects. As research into peptide-based therapies expands, the potential for peptide antibiotics to be used in personalized treatment regimens will continue to grow, further fueling market demand.

SCOPE OF STUDY:

The report analyzes the Peptide Antibiotics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Non-ribosomal Synthesized Peptide Antibiotics, Ribosomal Synthesized Peptide Antibiotics); Disease Type (Skin Infection, HABP / VABP, Blood Stream Infections, Other Disease Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • AbbVie Inc.
  • Acurx Pharmaceuticals
  • ANI Pharmaceuticals, Inc.
  • Antabio
  • BiomX
  • Clarametyx Biosciences
  • Cubist Pharmaceuticals (acquired by Merck & Co.)
  • Cumberland Pharmaceuticals Inc.
  • Eli Lilly and Company
  • GSK plc.
  • Melinta Therapeutics
  • Merck & Co., Inc.
  • MinervaX
  • Pfizer Inc.
  • Sandoz AG
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • The Menarini Group
  • Venatorx Pharmaceuticals
  • Xellia Pharmaceuticals

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Peptide Antibiotics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Multidrug-Resistant Pathogens Throws the Spotlight on Peptide Antibiotics as Next-Generation Therapeutics
    • Growing Global Burden of Antimicrobial Resistance (AMR) Propels Demand for Novel Peptide-Based Antibiotic Classes
    • Strategic Shifts in Pharmaceutical R&D Portfolios Strengthen Business Case for Peptide Antibiotic Investments
    • Favorable Regulatory Incentives and Fast-Track Designations Accelerate Clinical Development of Peptide Antibiotics
    • Expansion of Hospital-Acquired Infections (HAIs) Worldwide Expands Addressable Market Opportunity for Peptide-Based Solutions
    • Technological Advancements in Peptide Synthesis Drive Down Production Costs and Spur Market Penetration
    • Growing Adoption of Synthetic Biology and Recombinant Technologies Drives Innovation in Peptide Antibiotic Manufacturing
    • Surge in Personalized Medicine and Targeted Therapies Enhances Commercial Viability of Precision-Designed Peptides
    • Growing Interest in Narrow-Spectrum Antibiotics Sustains Growth Momentum for Selective Peptide Therapeutics
    • Increasing Government and Global Health Organization Funding Strengthens Pipeline for Antimicrobial Peptides
    • Demand for Antibiotics With Low Resistance Profiles Generates Strong Interest in Peptide-Based Modalities
    • Rise in Zoonotic and Emerging Infectious Diseases Expands Strategic Use-Cases for Broad-Spectrum Peptide Antibiotics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Peptide Antibiotics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Peptide Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Peptide Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Peptide Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Non-ribosomal Synthesized Peptide Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Non-ribosomal Synthesized Peptide Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Non-ribosomal Synthesized Peptide Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Ribosomal Synthesized Peptide Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Ribosomal Synthesized Peptide Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Ribosomal Synthesized Peptide Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Skin Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Skin Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Skin Infection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for HABP / VABP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for HABP / VABP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for HABP / VABP by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Blood Stream Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Blood Stream Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Blood Stream Infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Peptide Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • JAPAN
    • Peptide Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CHINA
    • Peptide Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • EUROPE
    • Peptide Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Peptide Antibiotics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Peptide Antibiotics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Peptide Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • FRANCE
    • Peptide Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • GERMANY
    • Peptide Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Peptide Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Peptide Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Peptide Antibiotics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Peptide Antibiotics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Peptide Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Peptide Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • INDIA
    • Peptide Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Peptide Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Peptide Antibiotics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Peptide Antibiotics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Peptide Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Peptide Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Peptide Antibiotics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Peptide Antibiotics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Peptide Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AFRICA
    • Peptide Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION